9 completed, 3 recruiting, 1 active not recruiting, 1 withdrawn. 5 Phase 3, 3 Phase 2, 2 Phase 4, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Recruiting 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 4 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow anti-inhibitor coagulant complex: new trials by email Literature Review of anti-inhibitor coagulant complex trials Research Report on anti-inhibitor coagulant complex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis Emicizumab, FEIBA, rFVIIa - Hemophilia A | Phase 3 | Recruiting | Emory University | 5 | 2026-09-01 | 2026-08-21 |
| Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery FEIBA, FFP - Cardiac Disease, Surgery | Phase 2 | Recruiting | Northwell Health | 140 | 2025-11-03 | 2026-03-11 |
| FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients FEIBA, Placebo - Cardiac Disease | Phase 2 | Withdrawn | Mayo Clinic | 2021-10-01 | 2022-12-05 | |
| A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab Feiba - Hemophilia A With Inhibitor | Phase 4 | Active not recruiting | Children's Hospital Los Angeles | 20 | 2020-07-01 | 2022-03-09 |
| Treatment of Hemophilia A Patients With FVIII Inhibitors Nuwiq, Octanate, Wilate - Hemophilia A | Recruiting | Emory University | 120 | 2020-03-17 | 2026-09-23 | |
| FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) FEIBA - Hemophilia A or B With Inhibitors | Phase 3 | Completed | Baxalta now part of Shire | 45 | 2019-02-12 | 2023-02-14 |
| FEIBA and Use of Blood Products in Cardiac Surgery FEIBA, Normal Saline - Cardiovascular Disease | Phase 1 | Completed | Oregon Health and Science University | 12 | 2016-02-01 | 2020-07-14 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors Emicizumab, rFVIIa, aPCC - Hemophilia A | Phase 3 | Completed | Hoffmann-La Roche | 113 | 2015-11-18 | 2021-06-24 |
| Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed fixed-dose activated prothrombin complex concentrate, variable-dose inactivated prothrombin complex concentrate - Hemorrhage | Completed | Rush University Medical Center | 342 | 2015-10-01 | 2017-10-25 | |
| Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) - Hemophilia A or B With Inhibitors, Hemophilia A | Phase 3 | Completed | Baxalta now part of Shire | 52 | 2009-03-31 | 2021-05-19 |
| Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX activated recombinant human factor VII, Feiba VH - Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Completed | Novo Nordisk A/S | 52 | 2008-06-01 | 2016-11-17 | |
| Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors activated prothrombin complex concentrate (FEIBA) - Hemophilia A With Inhibitors | Phase 2 / Phase 3 | Completed | Tulane University School of Medicine | 34 | 2003-06-01 | 2020-03-02 |
| Trial of NovoSeven® in Haemophilia - Joint Bleeds eptacog alfa (activated), Feiba VH - Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 4 | Completed | Novo Nordisk A/S | 42 | 2001-09-01 | 2017-01-12 |
| The FEIBA NovoSeven Comparative Study FEIBA and NovoSeven - Severe Hemophilia A With an Inhibitor | Not applicable | Completed | Skane University Hospital | 60 | 2000-07-01 | 2007-04-19 |
Hemophilia A (6) · Heart Diseases (2) · Hemophilia B (2) · Hemorrhage (2) · Cardiovascular Diseases (1) · Hematologic Diseases (1)
Baxalta now part of Shire (2) · Emory University (2) · Novo Nordisk A/S (2) · Children's Hospital Los Angeles (1) · Hoffmann-La Roche (1) · Mayo Clinic (1) · Northwell Health (1) · Oregon Health and Science University (1) · Rush University Medical Center (1) · Skane University Hospital (1) · Tulane University School of Medicine (1)
United States (10) · Croatia (2) · Germany (2) · Japan (2) · New Zealand (2) · Poland (2) · Ukraine (2) · Australia (1) · Brazil (1) · Bulgaria (1) · Costa Rica (1) · France (1) · Italy (1) · North Macedonia (1) · Romania (1)
Cindy A Leissinger (1) · Elena Ashikhmina, MD, PhD (1) · Erik Berntorp, MD, PhD (1) · Gary D Peksa, PharmD (1) · Guy Young, MD (1) · Pey-Jen Yu (1) · Robert Mokszycki, PharmD (1) · Robert Sidonio, MD (1) · Robert Sidonio, MD, MSc (1)
PMID 16990605, PMID 18081834, PMID 22047559, PMID 23551918, PMID 23731246, PMID 23910578, PMID 28691557, PMID 34215339, PMID 34589194, PMID 35939785
2015 (2), 2008 (1)